Mirum Pharmaceuticals, Inc. (MIRM) Institutional Ownership

Ownership Summary

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has 277 institutional investors that have filed 13F reports for the period ending December 2025.

• These investors held 104.3% of outstanding shares in December 2025, up from 101.6% in September 2025.
• They increased total shares held in Mirum Pharmaceuticals by 8.56% from the prior quarter, while the number of investors in MIRM increased 35.12% year over year.
• During the quarter, 160 of these 277 funds increased positions in MIRM, 81 reduced exposure, and 36 held steady.
• Combined, these investors held 59.46Mn shares in MIRM for December 2025, up by 4.69Mn shares quarter on quarter, and up 4.66Mn shares year over year.
• Frazier Life Sciences Management, L.P. is the top holder of Mirum Pharmaceuticals as of December 31, 2025, with 6.8Mn shares representing 11.92% of outstanding stock.
• The most significant purchases of MIRM for the quarter ending December 2025 came from Janus Henderson Group Plc (1.07Mn), Goldman Sachs Group Inc (997.8K), State Street Corp (797.09K), WELLINGTON MANAGEMENT GROUP LLP (447.14K), Soleus Capital Management, L.P. (424.92K).
• Top sellers of MIRM stock for the quarter ending December 2025 included Point72 Asset Management, L.P. (600.04K), EVENTIDE ASSET MANAGEMENT, LLC (428.98K), Barclays Plc (335.32K), Morgan Stanley (244.46K), ARROWSTREET CAPITAL, LIMITED PARTNERSHIP (239.81K).
• Business Quant data shows the 10 biggest positions in Mirum Pharmaceuticals as of December 2025 are held by Frazier Life Sciences Management, L.P. (6.8Mn), Janus Henderson Group Plc (6.07Mn), BlackRock, Inc. (3.65Mn), VANGUARD GROUP INC (2.6Mn), State Street Corp (2.14Mn), EVENTIDE ASSET MANAGEMENT, LLC (2.09Mn), BVF INC/IL (1.5Mn), Goldman Sachs Group Inc (1.45Mn), Novo Holdings A/S (1.26Mn), WELLINGTON MANAGEMENT GROUP LLP (1.24Mn).